Maturity Onset Diabetes of the Young (MODY)

Definition and Clinical Hallmarks

Maturity-Onset Diabetes of the Young (MODY) constitutes a heterogeneous group of monogenic diabetes syndromes characterized by a primary genetic defect in pancreatic beta-cell function and insulin secretion.
It accounts for approximately 2% to 5% of all pediatric and youth-onset diabetes cases and roughly 0.4% of diabetes overall.
The clinical presentation is typically defined by an early onset of diabetes, most often before 25 to 30 years of age, though usually manifesting after 8 to 10 years of age.
It demonstrates a strong autosomal dominant inheritance pattern, frequently with affected family members spanning two to three consecutive generations.
Patients generally exhibit “mild” diabetes, characterized by an initial Hemoglobin A1c (HbA1c) of less than 10%, an absence of significant ketosis, and persistently low insulin requirements (less than 0.5 U/kg/day).
Diagnosis is strongly suspected in the complete absence of pancreatic islet autoantibodies (e.g., GAD65, IA-2, ZnT8, ICA) and a lack of classic insulin resistance markers such as significant obesity or acanthosis nigricans.
Affected individuals typically retain significant, albeit impaired, residual endogenous insulin secretion, which is reflected by preserved serum C-peptide levels.

Pathogenic variants in at least 14 different genes have been identified as causing MODY, with mutations in four specific genes (MODY 1, 2, 3, and 5) accounting for nearly 90% of all confirmed cases.

MODY 2 is caused by heterozygous inactivating mutations in the glucokinase (GCK) gene located on chromosome 7.
Glucokinase functions as the primary “glucose sensor” for the pancreatic beta cell; an inactivating mutation shifts the threshold for glucose-stimulated insulin release to a higher set point.
This results in a distinct phenotype of mild, persistent, and non-progressive fasting hyperglycemia (typically 110–140 mg/dL) present from birth.
The HbA1c is remarkably stable and rarely exceeds 7.5%.
Because the hyperglycemia is mild and stable, patients carry an extremely low lifetime risk of developing diabetic microvascular complications.

MODY 3 is the most common form of treatment-requiring MODY (accounting for 30% to 60% of cases) and is caused by mutations in the hepatocyte nuclear factor-1-alpha (HNF1A) gene on chromosome 12.
Patients with MODY 3 frequently exhibit lowered renal thresholds for glucose, presenting with prominent glycosuria.
MODY 1 is a less common variant caused by mutations in the hepatocyte nuclear factor-4-alpha (HNF4A) gene on chromosome 20.
A unique historical clue for MODY 1 is a history of large birth weight (macrosomia) and transient hyperinsulinemic hypoglycemia during the neonatal period.
Unlike MODY 2, both MODY 1 and MODY 3 are characterized by progressive beta-cell failure; hyperglycemia worsens over time, and patients are at a high risk for developing long-term microvascular and macrovascular complications dependent on their metabolic control.

MODY 5 is caused by mutations or large deletions in the hepatocyte nuclear factor-1-beta (HNF1B) gene on chromosome 17.
It presents as a syndromic form of diabetes characterized prominently by extrapancreatic manifestations, most notably structural genitourinary malformations and renal cysts, which often precede the onset of diabetes.

A high index of clinical suspicion must be maintained for lean, autoantibody-negative patients presenting with a strong multi-generational family history of diabetes.
Definitive diagnosis strictly mandates molecular genetic testing to identify the exact pathogenic variant, as the specific genetic etiology profoundly dictates the optimal therapeutic approach and prognosis.

MODY 2 (GCK): Because the condition is non-progressive, patients generally require absolutely no pharmacological treatment or dietary modification. The only exception is during pregnancy; insulin therapy may be indicated if serial ultrasounds demonstrate accelerated fetal growth, implying an unaffected fetus is being exposed to maternal hyperglycemia.
MODY 1 (HNF4A) and MODY 3 (HNF1A): Patients exhibit profound sensitivity to low doses of oral sulfonylureas (e.g., glyburide or glipizide), which serve as the highly effective, first-line pharmacologic treatment. As the disease relentlessly progresses, additional therapies, and eventually exogenous insulin, may be required to maintain glycemic targets.
MODY 5 (HNF1B): Patients do not typically respond to oral sulfonylureas and universally require the initiation of exogenous insulin therapy to manage their hyperglycemia.